THIS IS MORE THAN HOPE
Patients diagnosed with non-Hodgkin lymphoma are told they’ll achieve remission with first-line chemotherapy. But about 50% of them don’t, as their cancer resists treatment after treatment. They are running out of options…and hope. They need a reason to believe complete remission can still exist after treatment failure. YESCARTA is the first CAR T-cell therapy approved for NHL. It can give appropriate 3rd-line patients something more than hope––it can give them a chance for complete remission. With a strategically choreographed ecosystem focused on messages of empowerment and hope, we are able to provide patients with the resources they need to fight for their survival.
Our goal was to give patients not only hope, but a chance for real remission. Together, with patients and oncologists, we are all succeeding.
PRINT THAT EDUCATES AND ACTIVATES
3 key barriers stand between potential patients and YESCARTA:
- Lack of knowledge regarding CAR T therapy and when it’s an option
- Lack of hope that this treatment will be any different than what has already failed them
- Lack of support needed to self-refer to an Authorized Treatment Center
The YESCARTA print pieces arm patients with the hope, knowledge, and empowerment needed to overcome these barriers.
The YESCARTA Brochure communicates what CAR T-cell therapy is, how it works, and its efficacy in a way that’s digestible and easy for a patient to understand.
To help patients discuss CAR T-cell therapy with their community oncologist, the doctor discussion tool provides questions to guide the conversation and remove barriers for a referral to an Authorized Treatment Center.
The NHL treatment journey can be complex, and most patients don’t understand what a third-line treatment means or when its available to them. A patient-friendly algorithm explains the different treatment options available and when it’s the right time to ask for YESCARTA. Understanding this information plays a key role in empowering patients to request a referral or self-refer to an Authorized Treatment Center.
THE POWER OF PATIENT SELF ADVOCACY
Despite a very small patient population, YESCARTA made an outsized impact. These numbers represent more than campaign results—they represent lives saved.
PATIENT POPULATION: 8,400
UNIQUE SITE VISITS